Exhibit 99.1
Ardelyx Reports Third Quarter 2020 Financial Results and
Business Highlights
Tenapanor NDA Accepted for Review by FDA; PDUFA Goal Date set for April 29, 2021
Maintains strong balance sheet with $185.5 million in cash, cash equivalents and short-term investments
FREMONT, Calif., November 5, 2020 -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today reported business highlights and financial results for the third quarter ended September 30, 2020.
“The FDA’s acceptance of our New Drug Application for tenapanor is a major milestone that continues our progress toward the potential launch of this novel therapeutic for the many dialysis patients who struggle with controlling hyperphosphatemia.” said Mike Raab, president and chief executive officer of Ardelyx. “Our commitment to this field was further highlighted in clinical data presented at ASN Kidney Week 2020 generated by Ardelyx and our Japanese partner KKC, supporting the clinical safety and efficacy of tenapanor and reinforcing its potential to transform the treatment landscape for patients.”
Recent Business and Pipeline Updates
| ● | The United States Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for tenapanor to control serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis with a Prescription Drug User Fee Act (“PDUFA”) goal date of April 29, 2021. The filing was supported by three successful Phase 3 studies demonstrating tenapanor’s ability to reduce phosphate levels, with two trials evaluating tenapanor as a monotherapy and the third evaluating tenapanor as part of a dual mechanism approach with phosphate binders. |
| ● | Presented new clinical data supporting the clinical safety and efficacy of tenapanor at ASN Kidney Week 2020. Three poster presentations highlighted data from Phase 3 trials conducted by Ardelyx, including the BLOCK, AMPLIFY and PHREEDOM studies. Additionally, the company's partner for tenapanor in Japan, Kyowa Kirin Co., Ltd., presented the results from two Phase 2 studies evaluating the efficacy and safety of tenapanor in Japanese patients on hemodialysis. |
Third Quarter 2020 Financial Results
| ● | Cash Position: As of September 30, 2020, Ardelyx had total cash, cash equivalents and short-term investments of $185.5 million, as compared to total cash, cash equivalents and short-term investments of $247.5 million as of December 31, 2019. |
| ● | Revenue: The company generated $2.7 million in revenue during the three months ended September 30, 2020, which primarily represents collaborative development revenue and sales of tenapanor for clinical supply to KKC. |
| ● | R&D Expenses: Research and development expenses were $12.2 million for the three months ended September 30, 2020, a decrease of approximately $5.4 million, or 30 percent, compared to $17.6 million for the three months ended September 30, 2019. The decrease was primarily due to the |
| completion of the Phase 3 PHREEDOM and AMPLIFY clinical trials evaluating tenapanor for the control of hyperphosphatemia. |
| ● | G&A Expenses: General and administrative expenses were $7.6 million for the three months ended September 30, 2020, an increase of $0.7 million, or approximately 10 percent, compared to $6.9 million for the three months September 30, 2019. The increase was primarily due to an increase in costs associated with building and staffing our commercial infrastructure and teams as we prepare for the anticipated U.S. launch of tenapanor for the control of serum phosphorus in CKD patients on dialysis. |
| ● | Net Loss: Net loss for the quarter ended September 30, 2020 was $18.1 million, or ($0.20) per common share, as compared to $23.5 million, or ($0.37) per common share, for the quarter ended September 30, 2019. |
About Ardelyx, Inc.
Ardelyx is focused on developing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiovascular diseases. Ardelyx is advancing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, for which the company’s NDA is currently under review by the FDA, with a PDUFA goal date of April 29, 2021. Ardelyx is also advancing RDX013, a potassium secretagogue program, for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. In addition, Ardelyx received FDA approval of IBSRELA® (tenapanor) on September 12, 2019. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in the respective territories.
Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995, including statements regarding the potential for the use of tenapanor as monotherapy and as part of a dual mechanism approach with tenapanor and phosphate binders for the treatment of hyperphosphatemia. Such forward-looking statements involve substantial risks and uncertainties that could cause Ardelyx’s future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties associated with the regulatory approval process and uncertainties in the drug commercialization process. Ardelyx undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ardelyx’s business in general, please refer to Ardelyx’s Quarterly Report on Form 10-Q to be filed with the Securities and Exchange Commission on November 5, 2020, and its future current and periodic reports to be filed with the Securities and Exchange Commission.
Investor and Media Contacts:
Kimia Keshtbod
kkeshtbod@ardelyx.com
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Alex Santos
Wheelhouse Life Science Advisors
asantos@wheelhouselsa.com
Ardelyx, Inc.
Condensed Balance Sheets
(In thousands)
| September 30, |
| December 31, | |||
| (Unaudited) | | (1) | |||
Assets | | | | | | |
Cash and cash equivalents | | $ | 91,009 | | $ | 181,133 |
Short-term investments | | | 94,488 | | | 66,379 |
Unbilled revenue | | | 750 | | | 750 |
Property and equipment, net | | | 2,111 | | | 3,436 |
Right-of-use assets | | | 2,402 | | | 3,970 |
Prepaid and other assets | | | 7,795 | | | 4,114 |
Total assets | | $ | 198,555 | | $ | 259,782 |
| | | | | | |
Liabilities and stockholders’ equity | | | | | | |
Accounts payable | | $ | 2,490 | | $ | 2,187 |
Accrued compensation and benefits | | | 3,722 | | | 4,453 |
Current portion of operating lease liability | | | 2,770 | | | 2,608 |
Loan payable, current portion | | | — | | | 1,183 |
Deferred revenue | | | 885 | | | 4,541 |
Accrued expenses and other liabilities | | | 6,667 | | | 7,248 |
Operating lease liability, net of current portion | | | — | | | 2,076 |
Loan payable, net of current portion | | | 50,681 | | | 48,831 |
Stockholders’ equity | | | 131,340 | | | 186,655 |
Total liabilities and stockholders’ equity | | $ | 198,555 | | $ | 259,782 |
| (1) | Derived from the audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. |
Ardelyx, Inc.
Condensed Statements of Operations
(Unaudited)
(In thousands, except share and per share amounts)
| | Three Months Ended September 30, | | Nine Months Ended September 30, | ||||||||
|
| 2020 |
| 2019 |
| 2020 |
| 2019 | ||||
Revenues: |
| | | | | | | | | | | |
Licensing revenue | | $ | — | | $ | 3,000 | | $ | 706 | | $ | 3,000 |
Collaborative development revenue | | | 1,356 | | | — | | | 3,656 | | | — |
Other revenue | | | 1,357 | | | 13 | | | 1,400 | | | 31 |
Total revenues | | | 2,713 | | | 3,013 | | | 5,762 | | | 3,031 |
Operating expenses: | |
| | | | | | | | | | |
Cost of revenue | |
| — | | | 600 | | | 141 | | | 600 |
Research and development | | | 12,240 | | | 17,580 | | | 46,948 | | | 57,436 |
General and administrative | |
| 7,634 | | | 6,922 | | | 21,810 | | | 17,410 |
Total operating expenses | |
| 19,874 | | | 25,102 | | | 68,899 | | | 75,446 |
Loss from operations | |
| (17,161) | | | (22,089) | | | (63,137) | | | (72,415) |
Interest expense | | | (1,202) | | | (1,443) | | | (3,785) | | | (4,328) |
Other income, net | |
| 255 | | | 294 | | | 1,485 | | | 1,896 |
Loss before provision for income taxes | |
| (18,108) | | | (23,238) | | | (65,437) | | | (74,847) |
Provision for income taxes | |
| — | | | 301 | | | — | | | 303 |
Net loss | | $ | (18,108) | | $ | (23,539) | | $ | (65,437) | | $ | (75,150) |
Net loss per common share, basic and diluted | | $ | (0.20) | | $ | (0.37) | | $ | (0.73) | | $ | (1.20) |
Shares used in computing net loss per share - basic and diluted | |
| 89,365,798 | | | 62,828,513 | | | 89,109,772 | | | 62,676,591 |